Within Major Pharmaceutical Preparations industry Novelion Therapeutics Inc booked the highest Quick Ratio than Novelion Therapeutics Inc in the first quarter 2019. While total ranking remained the same in the Q1 2019 compared to the fourth quarter 2018 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents NVLN�s has?
What are NVLN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NVLN Quick Ratio	(Mar 31 2019) Q1	(Dec 31 2018) Q4	(Sep 30 2018) Q3	(Jun 30 2018) Q2	(Mar 31 2018) Q1
Y / Y Current Liabilities Change	781.79 %	637.6 %	554.35 %	-49.49 %	-52.67 %
Y / Y Cash & cash equivalent Change	-	-18.91 %	-61.44 %	-52.13 %	-38.84 %
Quick Ratio MRQ	-	0.11	0.07	0.71	1.03
NVLN's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	8.06 %	10.66 %	560.21 %	11.7 %	-9.61 %
Seq. Cash & cash equivalent Change	-	64.93 %	-31.51 %	-23.1 %	-6.64 %

Quick Ratio first quarter 2019 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Novelion Therapeutics Inc 's Current Liabilities	$ 443 Millions	Visit NVLN's Balance sheet
Novelion Therapeutics Inc 's Cash & cash equivalent	$ 0 Millions	Visit NVLN's Balance sheet
Source of NVLN's Sales		Visit NVLN's Sales by Geography

Cumulative Novelion Therapeutics Inc 's Quick Ratio

NVLN's Quick Ratio for the trailling 12 Months

NVLN Quick Ratio	(Mar 31 2019) 12 Months	(Dec 31 2018) 12 Months	(Sep 30 2018) 12 Months	(Jun 30 2018) 12 Months	(Mar 31 2018) 12 Months
Y / Y Current Liabilities TTM Growth	367.78 %	169.18 %	35.63 %	-34.94 %	21.66 %
Y / Y Cash & cash equivalent TTM Growth	-57.09 %	-44.28 %	-49.83 %	-21.3 %	34.93 %
Quick Ratio TTM	0.09	0.19	0.33	1	0.96
Total Ranking TTM	# 5294	# 2398	# 5174	# 4611	# 5069
Seq. Current Liabilities TTM Growth	44.29 %	66.56 %	143.61 %	-20.1 %	-16.97 %
Seq. Cash & cash equivalent TTM Growth	-31.6 %	-6.02 %	-19.95 %	-16.6 %	-11.18 %

Quick ratio ranking by company, industry and sector >> Back to NVLN Financial Strength Comparisons >> Go to Compare NVLN Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2019 to $443.46 millions, cumulative Quick Ratio decreased to 0.09 below the Novelion Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 470 other companies have achieved higher Quick Ratio than Novelion Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2018 from 2398 to 5294.

Explain Quick Ratio?
How much Cash & cash equivalents NVLN�s has?
What are NVLN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 471
Healthcare Sector	# 925
Within the Market	# 5294

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.82	0.54	0.09
(Sep 30 2017)		(Mar 31 2019)

Companies with similar Quick Ratio in the quarter ending Mar 31 2019, within Major Pharmaceutical Preparations Industry

Quick Ratio

Mar 31 2019 MRQ Cash & cash equivalent

Mar 31 2019 MRQ Current Liabilities

Date modified: 2026-09-08T15:09:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.